Good morning, and welcome to Procter & Gamble’s quarter-end conference call. Today’s event is being recorded for replay. This ...

Despite its longstanding role in treating allergies, motion sickness and cold symptoms, diphenhydramine, best known by its ...

Throughout the last three months, 6 analysts have evaluated Kenvue KVUE, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ...

Shares of Kenvue Inc. KVUE rallied 1.51% to $22.84 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 6,388.64 ...

Kenvue's operational struggles and accelerating negative momentum make the stock unattractive, despite its iconic brands and seemingly defensive business model. The company's high leverage, weak ...

Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and r ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more here.

NEW YORK (Reuters) -Uncertainty over Federal Reserve Chair Jerome Powell’s tenure is prompting investors to assess potential market reactions should there be an premature change in leadership at ...

Kenvue says that Thibaut Mongon is stepping down as its CEO as the maker of Listerine and Band-Aid brands continues with a strategic review of the company.

This has pushed companies like Kenvue into the bargain bin. In sum, Kenvue is reasonably valued and offers a generous yield for investors seeking passive income.